AbCellera Biologics Inc.ABCLNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank14
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Percentile
P14
Within normal range
vs 5Y Ago
-21.7x
Contraction
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
2025$-174.07M+6.9%
2024$-186.95M-54.0%
2023$-121.38M-159.3%
2022$204.70M+10.0%
2021$186.13M+2221.7%
2020$8.02M+715.3%
2019$-1.30M+25.2%
2018$-1.74M-